2026-2034年全球肺炎治疗市场规模、份额、趋势和成长分析报告

预计肺炎治疗市场将从 2025 年的 32.8 亿美元成长到 2034 年的 75.2 亿美元，2026 年至 2034 年的复合年增长率为 9.66%。

全球呼吸道感染疾病的高发生率正推动全球肺炎治疗市场稳定成长。肺炎仍然是导致发病率和死亡率的主要原因之一，尤其是在儿童和老年人群中。人们对早期诊断和及时治疗的认识不断提高，推动了对抗生素、抗病毒药物和辅助疗法的需求。发展中地区医疗保健覆盖范围的扩大也进一步促进了市场成长。

关键成长要素包括疫苗接种率的提高、医疗保健支出的增加以及抗生素研发的进步。製药公司正在投资开发对抗抗生素抗药性的新治疗方法。此外，以呼吸系统疾病管理为重点的公共卫生政策也有助于提高患者获得治疗的机会。诊断工具的改进也有助于提高治疗性介入的有效性。

展望未来，对标靶治疗和联合治疗的持续研究预计将对市场产生积极影响。疫苗接种计划的扩大将影响治疗模式。医疗基础设施不断完善的新兴市场具有很高的成长潜力。由于呼吸系统健康仍然是全球关注的重点，预计对肺炎治疗的需求将稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 渗透率和成长前景分析
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场挑战
• 波特五力分析
• PESTLE分析

第四章 全球肺炎治疗市场：依产品划分

• 市场分析、洞察与预测
• 药物
• 疫苗
• 氧气疗法

第五章：全球肺炎治疗市场：依感染疾病

• 市场分析、洞察与预测
• 院内获得性肺炎（HAP）
• 社区型肺炎（CAP）
• 人工呼吸器相关性肺炎（VAP）

第六章：全球肺炎治疗市场：依给药途径划分

• 市场分析、洞察与预测
• 口服
• 肠外
• 其他的

第七章：全球肺炎治疗市场：依最终用途划分

• 市场分析、洞察与预测
• 医院
• 居家照护
• 专科诊所
• 其他的

第八章 全球肺炎治疗市场：依地区划分

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第九章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商情况（基于现有资讯）
• 策略规划

第十章：公司简介

• 主要公司的市占率分析
• 公司简介
  • AstraZeneca
  • Eli Lilly And Company
  • F. Hoffmann-La Roche Ltd
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma
  • Lupin

The Pneumonia Therapeutics Market size is expected to reach USD 7.52 Billion in 2034 from USD 3.28 Billion (2025) growing at a CAGR of 9.66% during 2026-2034.

The Global Pneumonia Therapeutics Market is experiencing steady growth due to the high prevalence of respiratory infections worldwide. Pneumonia remains a significant cause of morbidity and mortality, particularly among children and elderly populations. Increasing awareness about early diagnosis and timely treatment is driving demand for antibiotics, antivirals, and supportive therapies. Expanding healthcare access in developing regions further supports market growth.

Key growth drivers include rising vaccination coverage, increasing healthcare expenditure, and advancements in antimicrobial drug development. Pharmaceutical companies are investing in novel therapies to address drug-resistant strains. Additionally, public health initiatives focused on respiratory disease management are boosting treatment accessibility. Improved diagnostic tools also contribute to effective therapeutic interventions.

Looking ahead, the market is expected to benefit from continued research into targeted and combination therapies. Increasing adoption of preventive vaccination programs will influence treatment patterns. Emerging markets improving healthcare infrastructure present strong growth potential. As respiratory health remains a global priority, pneumonia therapeutics demand is projected to grow steadily.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Drugs
• Vaccine
• Oxygen Therapy

By Infection

• Hospital-Acquired Pneumonia (HAP)
• Community-Acquired Pneumonia (CAP)
• Ventilator-Associated Pneumonia (VAP)

By Route of Administration

• Oral
• Parenteral
• Others

By End Use

• Hospitals
• Homecare
• Specialty Clinics
• Others

COMPANIES PROFILED

• AstraZeneca, Eli Lilly and Company, F HoffmannLa Roche Ltd, Mylan NV, Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Lupin
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PNEUMONIA THERAPEUTICS MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Vaccine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Oxygen Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PNEUMONIA THERAPEUTICS MARKET: BY INFECTION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Infection
• 5.2. Hospital-Acquired Pneumonia (HAP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Community-Acquired Pneumonia (CAP) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Ventilator-Associated Pneumonia (VAP) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PNEUMONIA THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PNEUMONIA THERAPEUTICS MARKET: BY END USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End Use
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PNEUMONIA THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Product
  • 8.2.2 By Infection
  • 8.2.3 By Route Of Administration
  • 8.2.4 By End Use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Product
  • 8.3.2 By Infection
  • 8.3.3 By Route Of Administration
  • 8.3.4 By End Use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Product
  • 8.4.2 By Infection
  • 8.4.3 By Route Of Administration
  • 8.4.4 By End Use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Product
  • 8.5.2 By Infection
  • 8.5.3 By Route Of Administration
  • 8.5.4 By End Use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Product
  • 8.6.2 By Infection
  • 8.6.3 By Route Of Administration
  • 8.6.4 By End Use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PNEUMONIA THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AstraZeneca
  • 10.2.2 Eli Lilly And Company
  • 10.2.3 F. Hoffmann-La Roche Ltd
  • 10.2.4 Mylan N.V
  • 10.2.5 Teva Pharmaceutical Industries Ltd
  • 10.2.6 Sanofi
  • 10.2.7 Novartis AG
  • 10.2.8 Sun Pharmaceutical Industries Ltd
  • 10.2.9 Aurobindo Pharma
  • 10.2.10 Lupin